On January 28, 2022, Homology Medicines, Inc. entered into an equity securities purchase agreement with a newly formed adeno-associated virus (AAV) vector manufacturing company (Newco), Oxford Biomedica (US), Inc. and Oxford Biomedica plc. Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.79 USD | +8.98% | +6.88% | +133.00% |
05-21 | Leerink Partners Starts Q32 Bio With Outperform Rating | MT |
05-09 | Q32 Bio Inc. Provides Corporate Update | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.00% | 305M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Announces Resignation of Tim Kelly as Chief Operating Officer